Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: Immediate and mid-term results

Dejan Orlic, Erminio Bonizzoni, Goran Stankovic, Flavio Airoldi, Alaide Chieffo, Nicola Corvaja, Giuseppe Sangiorgi, Massimo Ferraro, Carlo Briguori, Matteo Montorfano, Mauro Carlino, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Objectives This study evaluated clinical outcome after multivessel stenting with sirolimus-eluting stents (SES) in unselected lesions. Background Safety and effectiveness of multivessel SES implantation is currently unknown. Methods Major adverse cardiac events (MACE) (death, myocardial infarction [MI], and repeat revascularization) were analyzed at 30 days and at 6 months after multivessel SES implantation. Results In 155 consecutive patients, 573 SES were implanted in 3.3 ± 1.3 lesions per patient. At 30 days, the cumulative MACE rate was 10.3%: 7.1% patients developed a non-Q-wave MI, 1.9% developed a Q-wave MI, 0.6% died for non-cardiac reasons, and 0.6% had a repeat revascularization. Clinical follow-up was obtained in all 112 eligible patients treated for 359 lesions at a mean time of 6.5 ± 2.2 months. The cumulative MACE rate was 22.3%: 3 (2.7%) deaths (1 for cardiac reasons), 4 (3.6%) MIs, target lesion revascularization (TLR) in 16 (14.3%) patients with 24 (6.7%) lesions. Target vessel revascularization was required in 18 (16.1%) patients due to TLR of lesions treated with SES or to disease progression (1.8% of patients). Cox regression analysis revealed total stent length per patient as the most powerful independent predictor of MACE. Overall stent thrombosis occurred in three (1.9%) patients. Conclusions Multivessel SES implantation can be safely performed on patients with complex coronary artery disease. The need for revascularization increases because of the cumulative effect of TLR on patients with multiple lesions.

Original languageEnglish
Pages (from-to)1154-1160
Number of pages7
JournalJournal of the American College of Cardiology
Volume43
Issue number7
DOIs
Publication statusPublished - Apr 7 2004

Fingerprint

Sirolimus
Stents
Coronary Artery Disease
Therapeutics
Myocardial Infarction
Disease Progression
Thrombosis
Regression Analysis
Safety

Keywords

  • Bare metal stent
  • BMS
  • CABG
  • CK
  • Coronary artery bypass grafting
  • Creatine kinase
  • MACE
  • Major adverse cardiac events
  • MI
  • Myocardial infarction
  • PCI
  • Percutaneous coronary intervention
  • Percutaneous transluminal coronary angioplasty
  • PTCA
  • SES

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation : Immediate and mid-term results. / Orlic, Dejan; Bonizzoni, Erminio; Stankovic, Goran; Airoldi, Flavio; Chieffo, Alaide; Corvaja, Nicola; Sangiorgi, Giuseppe; Ferraro, Massimo; Briguori, Carlo; Montorfano, Matteo; Carlino, Mauro; Colombo, Antonio.

In: Journal of the American College of Cardiology, Vol. 43, No. 7, 07.04.2004, p. 1154-1160.

Research output: Contribution to journalArticle

Orlic, Dejan ; Bonizzoni, Erminio ; Stankovic, Goran ; Airoldi, Flavio ; Chieffo, Alaide ; Corvaja, Nicola ; Sangiorgi, Giuseppe ; Ferraro, Massimo ; Briguori, Carlo ; Montorfano, Matteo ; Carlino, Mauro ; Colombo, Antonio. / Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation : Immediate and mid-term results. In: Journal of the American College of Cardiology. 2004 ; Vol. 43, No. 7. pp. 1154-1160.
@article{2d74f14ff2af4e2ca39122b92ce5479a,
title = "Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: Immediate and mid-term results",
abstract = "Objectives This study evaluated clinical outcome after multivessel stenting with sirolimus-eluting stents (SES) in unselected lesions. Background Safety and effectiveness of multivessel SES implantation is currently unknown. Methods Major adverse cardiac events (MACE) (death, myocardial infarction [MI], and repeat revascularization) were analyzed at 30 days and at 6 months after multivessel SES implantation. Results In 155 consecutive patients, 573 SES were implanted in 3.3 ± 1.3 lesions per patient. At 30 days, the cumulative MACE rate was 10.3{\%}: 7.1{\%} patients developed a non-Q-wave MI, 1.9{\%} developed a Q-wave MI, 0.6{\%} died for non-cardiac reasons, and 0.6{\%} had a repeat revascularization. Clinical follow-up was obtained in all 112 eligible patients treated for 359 lesions at a mean time of 6.5 ± 2.2 months. The cumulative MACE rate was 22.3{\%}: 3 (2.7{\%}) deaths (1 for cardiac reasons), 4 (3.6{\%}) MIs, target lesion revascularization (TLR) in 16 (14.3{\%}) patients with 24 (6.7{\%}) lesions. Target vessel revascularization was required in 18 (16.1{\%}) patients due to TLR of lesions treated with SES or to disease progression (1.8{\%} of patients). Cox regression analysis revealed total stent length per patient as the most powerful independent predictor of MACE. Overall stent thrombosis occurred in three (1.9{\%}) patients. Conclusions Multivessel SES implantation can be safely performed on patients with complex coronary artery disease. The need for revascularization increases because of the cumulative effect of TLR on patients with multiple lesions.",
keywords = "Bare metal stent, BMS, CABG, CK, Coronary artery bypass grafting, Creatine kinase, MACE, Major adverse cardiac events, MI, Myocardial infarction, PCI, Percutaneous coronary intervention, Percutaneous transluminal coronary angioplasty, PTCA, SES",
author = "Dejan Orlic and Erminio Bonizzoni and Goran Stankovic and Flavio Airoldi and Alaide Chieffo and Nicola Corvaja and Giuseppe Sangiorgi and Massimo Ferraro and Carlo Briguori and Matteo Montorfano and Mauro Carlino and Antonio Colombo",
year = "2004",
month = "4",
day = "7",
doi = "10.1016/j.jacc.2003.10.052",
language = "English",
volume = "43",
pages = "1154--1160",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation

T2 - Immediate and mid-term results

AU - Orlic, Dejan

AU - Bonizzoni, Erminio

AU - Stankovic, Goran

AU - Airoldi, Flavio

AU - Chieffo, Alaide

AU - Corvaja, Nicola

AU - Sangiorgi, Giuseppe

AU - Ferraro, Massimo

AU - Briguori, Carlo

AU - Montorfano, Matteo

AU - Carlino, Mauro

AU - Colombo, Antonio

PY - 2004/4/7

Y1 - 2004/4/7

N2 - Objectives This study evaluated clinical outcome after multivessel stenting with sirolimus-eluting stents (SES) in unselected lesions. Background Safety and effectiveness of multivessel SES implantation is currently unknown. Methods Major adverse cardiac events (MACE) (death, myocardial infarction [MI], and repeat revascularization) were analyzed at 30 days and at 6 months after multivessel SES implantation. Results In 155 consecutive patients, 573 SES were implanted in 3.3 ± 1.3 lesions per patient. At 30 days, the cumulative MACE rate was 10.3%: 7.1% patients developed a non-Q-wave MI, 1.9% developed a Q-wave MI, 0.6% died for non-cardiac reasons, and 0.6% had a repeat revascularization. Clinical follow-up was obtained in all 112 eligible patients treated for 359 lesions at a mean time of 6.5 ± 2.2 months. The cumulative MACE rate was 22.3%: 3 (2.7%) deaths (1 for cardiac reasons), 4 (3.6%) MIs, target lesion revascularization (TLR) in 16 (14.3%) patients with 24 (6.7%) lesions. Target vessel revascularization was required in 18 (16.1%) patients due to TLR of lesions treated with SES or to disease progression (1.8% of patients). Cox regression analysis revealed total stent length per patient as the most powerful independent predictor of MACE. Overall stent thrombosis occurred in three (1.9%) patients. Conclusions Multivessel SES implantation can be safely performed on patients with complex coronary artery disease. The need for revascularization increases because of the cumulative effect of TLR on patients with multiple lesions.

AB - Objectives This study evaluated clinical outcome after multivessel stenting with sirolimus-eluting stents (SES) in unselected lesions. Background Safety and effectiveness of multivessel SES implantation is currently unknown. Methods Major adverse cardiac events (MACE) (death, myocardial infarction [MI], and repeat revascularization) were analyzed at 30 days and at 6 months after multivessel SES implantation. Results In 155 consecutive patients, 573 SES were implanted in 3.3 ± 1.3 lesions per patient. At 30 days, the cumulative MACE rate was 10.3%: 7.1% patients developed a non-Q-wave MI, 1.9% developed a Q-wave MI, 0.6% died for non-cardiac reasons, and 0.6% had a repeat revascularization. Clinical follow-up was obtained in all 112 eligible patients treated for 359 lesions at a mean time of 6.5 ± 2.2 months. The cumulative MACE rate was 22.3%: 3 (2.7%) deaths (1 for cardiac reasons), 4 (3.6%) MIs, target lesion revascularization (TLR) in 16 (14.3%) patients with 24 (6.7%) lesions. Target vessel revascularization was required in 18 (16.1%) patients due to TLR of lesions treated with SES or to disease progression (1.8% of patients). Cox regression analysis revealed total stent length per patient as the most powerful independent predictor of MACE. Overall stent thrombosis occurred in three (1.9%) patients. Conclusions Multivessel SES implantation can be safely performed on patients with complex coronary artery disease. The need for revascularization increases because of the cumulative effect of TLR on patients with multiple lesions.

KW - Bare metal stent

KW - BMS

KW - CABG

KW - CK

KW - Coronary artery bypass grafting

KW - Creatine kinase

KW - MACE

KW - Major adverse cardiac events

KW - MI

KW - Myocardial infarction

KW - PCI

KW - Percutaneous coronary intervention

KW - Percutaneous transluminal coronary angioplasty

KW - PTCA

KW - SES

UR - http://www.scopus.com/inward/record.url?scp=11144355695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144355695&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2003.10.052

DO - 10.1016/j.jacc.2003.10.052

M3 - Article

C2 - 15063422

AN - SCOPUS:11144355695

VL - 43

SP - 1154

EP - 1160

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -